Skip to main content

14-12-2017 | HER2-targeted agents | Article

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE

Johnston SRD et al. J Clin Oncol 2018; 36(8): 741-748. doi:10.1200/JCO.2017.74.7824

Please log in to get access to this content

Related topics

Image Credits